|Articles|December 8, 2021
Supplements and Featured Publications
- Patients With Diabetes and Chronic Kidney Disease: ACE Inhibitor or ARB Treatment, Medical Costs for Disease Management, and the FINE-CKD Model to Evaluate Economic Value of Finerenone
- Volume 27
- Issue 20
eAppendix: ACE Inhibitor or ARB Treatment Among Patients With Diabetes and Chronic Kidney Disease
Advertisement
Supplementary Appendix
Articles in this issue
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
How Do GLP-1 Agonists Fit Into Stroke Care?
3
Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD
4
Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making
5
